Tocagen Inc (TOCA) Receives Average Rating of “Buy” from Brokerages

Tocagen Inc (NASDAQ:TOCA) has earned an average recommendation of “Buy” from the eight research firms that are currently covering the firm, Marketbeat Ratings reports. One research analyst has rated the stock with a hold rating and seven have assigned a buy rating to the company. The average 12-month price target among analysts that have issued a report on the stock in the last year is $22.80.

A number of brokerages recently issued reports on TOCA. BidaskClub upgraded shares of Tocagen from a “hold” rating to a “buy” rating in a research note on Tuesday. HC Wainwright set a $15.00 price target on shares of Tocagen and gave the stock a “buy” rating in a research note on Monday, November 12th. Zacks Investment Research upgraded shares of Tocagen from a “sell” rating to a “hold” rating in a research note on Saturday, November 10th. ValuEngine upgraded shares of Tocagen from a “hold” rating to a “buy” rating in a research note on Friday, November 2nd. Finally, B. Riley upped their price target on shares of Tocagen from $15.00 to $22.00 and gave the stock a “buy” rating in a research note on Thursday, September 20th.

Shares of NASDAQ:TOCA traded down $0.34 during midday trading on Monday, reaching $12.92. The company’s stock had a trading volume of 54,966 shares, compared to its average volume of 117,770. The company has a market capitalization of $264.58 million, a PE ratio of -4.86 and a beta of 2.98. Tocagen has a 12-month low of $7.52 and a 12-month high of $15.80. The company has a debt-to-equity ratio of 0.55, a current ratio of 5.83 and a quick ratio of 5.83.

Tocagen (NASDAQ:TOCA) last announced its quarterly earnings results on Thursday, November 8th. The company reported ($0.02) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.24) by $0.22. The company had revenue of $18.01 million for the quarter, compared to analysts’ expectations of $2.01 million. Tocagen had a negative net margin of 222.81% and a negative return on equity of 71.61%. Equities analysts anticipate that Tocagen will post -2.49 EPS for the current fiscal year.

A number of institutional investors and hedge funds have recently bought and sold shares of TOCA. BlackRock Inc. lifted its stake in Tocagen by 25.2% during the 3rd quarter. BlackRock Inc. now owns 1,413,285 shares of the company’s stock valued at $22,033,000 after acquiring an additional 284,518 shares during the period. Vanguard Group Inc. lifted its stake in Tocagen by 14.9% during the 3rd quarter. Vanguard Group Inc. now owns 787,550 shares of the company’s stock valued at $12,278,000 after acquiring an additional 101,874 shares during the period. 683 Capital Management LLC bought a new position in Tocagen during the 2nd quarter valued at about $467,000. Millennium Management LLC bought a new position in Tocagen during the 1st quarter valued at about $402,000. Finally, Dimensional Fund Advisors LP bought a new position in Tocagen during the 3rd quarter valued at about $481,000. Institutional investors and hedge funds own 29.68% of the company’s stock.

Tocagen Company Profile

Tocagen Inc, a clinical-stage cancer-selective gene therapy company, focuses on developing and commercializing product candidates designed to activate a patient's immune system against their cancer. Its cancer-selective gene therapy platform is built on retroviral replicating vectors (RRVs), which are designed to deliver therapeutic genes into the DNA of cancer cells.

Read More: Average Daily Trade Volume – What You Need to Know

Analyst Recommendations for Tocagen (NASDAQ:TOCA)

Receive News & Ratings for Tocagen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tocagen and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply